Reading view
EvoSkills: Self-Evolving Agent Skills via Co-Evolutionary Verification
Moir\'e Video Authentication: A Physical Signature Against AI Video Generation
Editing strigolactone hormone receptor for robust antiviral silencing in rice
Mean Masked Autoencoder with Flow-Mixing for Encrypted Traffic Classification
LDHA-driven lactate metabolism promotes MDSC activation and immunosuppressive microenvironment in prostate cancer
Oncogene, Published online: 01 April 2026; doi:10.1038/s41388-026-03737-5
LDHA-driven lactate metabolism promotes MDSC activation and immunosuppressive microenvironment in prostate cancerTwo-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes
Gut. 2026 Feb 9;75(3):576-587. doi: 10.1136/gutjnl-2025-337506.
ABSTRACT
BACKGROUND: Current guidelines recommend a two-step approach for risk stratification of metabolic dysfunction-associated steatotic liver disease (MASLD), starting with Fibrosis-4 index (FIB-4) followed by liver stiffness measurement (LSM) using vibration-controlled transient elastography (VCTE).
OBJECTIVE: To evaluate this approach for predicting advanced fibrosis and liver-related events (LREs) in patients with type 2 diabetes (T2D).
DESIGN: A prospective liver biopsy cohort of T2D patients with histologically confirmed MASLD from seven centres in China was used to assess diagnostic performance for advanced fibrosis. The international VCTE-Prognosis cohort, including T2D patients with MASLD who underwent VCTE at 16 centres in the USA, Europe and Asia, with longitudinal follow-up, was used to assess LREs, defined as hepatic decompensation or hepatocellular carcinoma.
RESULTS: 4781 participants were included. In the liver biopsy cohort (n=352; 22.2% with advanced fibrosis), applying LSM thresholds of <8 kPa and >12 kPa after FIB-4 classified patients into 63.4% low-risk, 9.4% intermediate-risk and 27.3% high-risk, with a correct classification rate of 71%. In the VCTE-Prognosis cohort (n=4429; median follow-up 51.3 (IQR 27.4-70.7) months), 140 (3.2%) patients developed LREs (110 (2.5%) with hepatic decompensation and 59 (1.3%) with hepatocellular carcinoma). The two-step approach classified 72.6%, 6.8% and 20.6% of patients into low-risk, intermediate-risk and high-risk groups, with corresponding 5-year cumulative LRE incidences of 0.7%, 0.9% and 11.8%. Refining classification of intermediate FIB-4 patients using LSM <10 kPa (low-risk) and >15 kPa (high-risk) reduced the intermediate-risk group to 5.6% while preserving predictive accuracy.
CONCLUSION: The non-invasive two-step approach of FIB-4 followed by LSM effectively stratifies MASLD-related advanced fibrosis and LREs risk in T2D. Applying LSM cut-offs of 10 and 15 kPa further optimises risk stratification for future LREs.
PMID:41911049 | DOI:10.1136/gutjnl-2025-337506
MCLR: Improving Conditional Modeling in Visual Generative Models via Inter-Class Likelihood-Ratio Maximization and Establishing the Equivalence between Classifier-Free Guidance and Alignment Objectives
Injecting Falsehoods: Adversarial Man-in-the-Middle Attacks Undermining Factual Recall in LLMs
Hierarchical Long Video Understanding with Audiovisual Entity Cohesion and Agentic Search
19-Hydroxybufalin Inhibits Gastric Cancer Cell Proliferation by Modulating Metabolic Reprogramming
J Proteome Res. 2026 Apr 3;25(4):2014-2023. doi: 10.1021/acs.jproteome.5c00983. Epub 2026 Mar 17.
ABSTRACT
OBJECTIVE: 19-Hydroxybufalin (19-H) is a natural bioactive compound with anticancer potential, but its molecular target and mechanism of action remain unclear. This study aimed to systematically evaluate its antigastric cancer activity and identify potential molecular targets.
METHODS: The antitumor effect of 19-H was evaluated in both in vitro and in vivo models. Multiomics analysis, thermal proteome profiling, molecular docking, and molecular dynamics simulations were employed to elucidate the mechanism of action. Functional assays were further conducted to validate the key target.
RESULTS: 19-H exhibited nanomolar-level inhibitory activity against various gastric cancer cell lines, significantly suppressing tumor growth in subcutaneous xenograft and patient-derived xenograft models. Multiomics analysis revealed that 19-H reshaped metabolic pathways in gastric cancer. TPP screening identified PLPP2 as a potential target with significantly increased thermal stability upon 19-H treatment. Molecular simulations further revealed that 19-H binds stably to the α-helical region of PLPP2.
CONCLUSIONS: 19-H exerts its antigastric cancer effect by targeting PLPP2 and remodeling the metabolic network. PLPP2 may represent a novel therapeutic target for gastric cancer.
PMID:41842934 | DOI:10.1021/acs.jproteome.5c00983
Spend Less, Reason Better: Budget-Aware Value Tree Search for LLM Agents
Language in the Flow of Time: Time-Series-Paired Texts Weaved into a Unified Temporal Narrative
Unveiling Downstream Performance Scaling of LLMs: A Clustering-Based Perspective
Flow Matching Meets Biology and Life Science: A Survey
<i>KRAS</i>-extrachromosomal DNA drives intratumoral heterogeneity in gastric cancer
Oncogene, Published online: 05 March 2026; doi:10.1038/s41388-026-03713-z
KRAS-extrachromosomal DNA drives intratumoral heterogeneity in gastric cancer